Article
Biotechnology & Applied Microbiology
Jijun Yu, Luoxuan Wang, Xiangya Kong, Yang Cao, Mengmeng Zhang, Zhaolin Sun, Yang Liu, Jing Wang, Beifen Shen, Xiaochen Bo, Jiannan Feng
Summary: Cancer vaccines have gained attention for their performance in preclinical and clinical settings. However, there is a need for improvement in predicting neoantigens. This study collected verified cancer antigen peptides and discussed the role of each dataset in algorithm improvement. A platform was designed for exploring cancer antigens.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Oncology
Francois Anna, Elodie Bole-Richard, Joel LeMaoult, Marie Escande, Martin Lecomte, Jean-Made Certoux, Philippe Souque, Francine Garnache, Olivier Adotevi, Pierre Langlade-Demoyen, Maria Loustau, Julien Caumartin
Summary: CAR-T cell immunotherapy is a breakthrough in treating hematological malignancies, but the lack of tumor-specific antigens and immunosuppressive tumor microenvironments remain major hurdles. A new study shows that HLA-G, acting as both an immune checkpoint and a tumor-specific antigen, could be a promising target for CAR-T cell therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
Ran Xu, Tong Lu, JiaYing Zhao, Jun Wang, Bo Peng, LinYou Zhang
Summary: This study identified genes associated with the prognosis of lung adenocarcinoma patients and positively correlated with antigen-presenting cell infiltration, and identified potential tumor antigens for mRNA vaccines in lung adenocarcinoma. Further analysis revealed that early-stage lung adenocarcinoma patients with high immune cell infiltration, high immune checkpoint expression, and low tumor mutation burden might benefit from mRNA vaccination. Four biomarkers were also identified to assess the suitability of mRNA vaccination.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Jayanth S. Shankara Narayanan, Tomoko Hayashi, Suna Erdem, Sara McArdle, Herve Tiriac, Partha Ray, Minya Pu, Zbigniew Mikulski, Aaron Miller, Karen Messer, Dennis Carson, Stephen Schoenberger, Rebekah R. White
Summary: The combination of IRE and CD40Ab treatment can significantly improve the prognosis of pancreatic cancer, prolong patient survival, activate dendritic cells, identify and inhibit the progression of metastatic disease.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
David Restle, Joseph Dux, Xiaoyu Li, Alexander J. Byun, Jennie K. Choe, Yan Li, Raj G. Vaghjiani, Carlos Thomas, Kyohei Misawa, Kay See Tan, David R. Jones, Navin K. Chintala, Prasad S. Adusumilli
Summary: In patients with lung adenocarcinoma, brain metastases have a more immune-suppressive tumor immune microenvironment compared to other metastases. Majority of patients with antigen expression in the primary tumor also have antigen expression in the metastases, although with heterogeneous intensity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Katerin Rojas, Mariona Baliu-Pique, Aranzazu Manzano, Cristina Saiz-Ladera, Vanesa Garcia-Barberan, Francisco J. Cimas, Pedro Perez-Segura, Atanasio Pandiella, Balazs Gyorffy, Alberto Ocana
Summary: This study identified a signature of 7 integrin genes that can recognize immune infiltrated and activated Basal-like and HER2+ breast cancers with a favorable prognosis.
Article
Pharmacology & Pharmacy
Chan Gyu Lee, TaeEun Kim, Sungyoul Hong, Jongwan Chu, Ju Eun Kang, Hee Geon Park, Jun Young Choi, Kyoung Song, Sun Young Rha, Soohyeon Lee, Joon-Seok Choi, Sun Min Kim, Hae Min Jeong, Young Kee Shin
Summary: This study aimed to construct recombinant IFN-beta-1a mutein immunocytokines to overcome the limitations of short in vivo half-life, systemic toxicity, and poor biophysical properties of IFNs as anticancer agents. Enhancements in productivity, biophysical properties, therapeutic index, and tumor-targeting ability were achieved, leading to potential clinical evaluation of the novel immunocytokine as a promising candidate for anticancer therapeutics.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Hanyang Li, He Fang, Li Chang, Shuang Qiu, Xiaojun Ren, Lidong Cao, Jinda Bian, Zhenxiao Wang, Yi Guo, Jiayin Lv, Zhihui Sun, Tiejun Wang, Bingjin Li
Summary: Various C2 domain-containing proteins are crucial in tumorigenesis, signaling, and protein-protein interactions. TC2N, a protein with tandem C2 domains, shows differential expression in different cancers and is associated with tumorigenesis. Tumor-associated antigens have been identified as potential diagnostic and therapeutic targets in cancer treatment with differences in their expression levels in cancerous and normal cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Nanoscience & Nanotechnology
Jieun Han, Jaesung Lim, Chi-Pin James Wang, Jun-Hyeok Han, Ha Eun Shin, Se-Na Kim, Dooyong Jeong, Sang Hwi Lee, Bok-Hwan Chun, Chun Gwon Park, Wooram Park
Summary: Cancer immunotherapy has great potential in fighting malignancies by utilizing the immune system. Messenger RNA (mRNA) is a versatile tool that can encode tumor-associated antigens, immune cell receptors, cytokines, and antibodies. Lipid nanoparticles (LNPs) have emerged as significant candidates for delivering mRNA in cancer immunotherapy, providing protection and enhancing intracellular delivery. This review summarizes recent advancements in LNP-based mRNA delivery systems, focusing on optimizing design and delivery strategies for mRNA-encoded therapeutics in cancer treatment. Challenges and future perspectives in improving the safety and efficacy of LNP-based mRNA cancer immunotherapies are also discussed.
Article
Immunology
Shuai Ma, Yixu Ba, Hang Ji, Fang Wang, Jianyang Du, Shaoshan Hu
Summary: This study identified TP53, IDH1, C3, and TCF12 as effective antigens for the development of anti-glioma mRNA vaccines. Additionally, four immune subtypes of glioma were consistently found in the TCGA data, each displaying diverse molecular, cellular, and clinical features.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Hua Zhong, Shuai Liu, Fang Cao, Yi Zhao, Jianguo Zhou, Feng Tang, Zhaohua Peng, Yangsheng Li, Shen Xu, Chunlin Wang, Guohua Yang, Zhi-Qiang Li
Summary: This study identified four potential antigens for anti-glioma mRNA vaccine production and discovered three immune subtypes (IS1-IS3) in glioma patients, showing significant differences in prognosis and immune characteristics. Patients in subtypes IS2 and IS3 demonstrated better outcomes than those in IS1, indicating the potential for tailored mRNA vaccination for applicable glioma recipients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Cong Liu, Dimitri Papukashvili, Yu Dong, Xingyun Wang, Xing Hu, Nuo Yang, Jie Cai, Fengfei Xie, Nino Rcheulishvili, Peng George Wang
Summary: This study identified potential antigens for effective mRNA vaccine design and built an immune landscape for accurate patient selection for mRNA vaccine therapy in CRC. The study also revealed significant cellular and molecular differences among different immune subtypes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Chiao-Hsu Ke, Yu-Shan Wang, Hsin-Chien Chiang, Hsin-Yi Wu, Wang-Jing Liu, Cheng-Chung Huang, Yi-Chun Huang, Chen-Si Lin
Summary: A platform was developed to enhance the immunogenicity of autologous cancer vaccines by transplanting tumors into immunodeficient mice, leading to diversified tumor antigenic topology. CT26/SCID cancer vaccines inhibited tumor growth, increased tumor infiltrating lymphocytes, and triggered Th-1 predominant immune responses. Notably, differentially expressed proteins in CT26/SCID cells revealed novel therapeutic targets that can stimulate cytotoxic T cells and suppress tumor proliferation. This study provides effective proof-of-concept for personalized cancer immunotherapy using ACVs.
Review
Oncology
Gary L. Simmons, Omar Castaneda Puglianini
Summary: Significant progress has been made in the treatment of multiple myeloma in the past two decades. T-cell-based therapies have transformed our view of the disease from incurable to potentially curable. These therapies are actively investigated in various types of cancers and are considered one of the most impactful advancements in cancer therapeutics. This review provides a summary of the efficacy, toxicity, and management of T-cell-based therapies, as well as ongoing efforts to improve survival outcomes for multiple myeloma patients.
Review
Immunology
Silvia D'Amico, Patrizia Tempora, Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi, Franco Locatelli, Doriana Fruci
Summary: This review discusses the significant clinical advances of immune checkpoint inhibitors (ICIs) in cancer patients. However, response rates to ICIs vary and do not always result in long-term tumor regression. Therefore, it is crucial to identify new targets and combination therapies to improve response rates and duration. The antigen processing and presentation (APP) pathway has been shown to be a key element in enhancing tumor immunogenicity and increasing the efficacy of ICI-based immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Sung-Jong Lee, Andrew Yang, T. -C. Wu, Chien-Fu Hung
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2016)
Article
Virology
Rosie T. Jiang, Joshua W. Wang, Shiwen Peng, Tsui-Chin Huang, Chenguang Wang, Fabiana Cannella, Yung-Nien Chang, Raphael P. Viscidi, Simon R. A. Best, Chien-Fu Hung, Richard B. S. Roden
JOURNAL OF VIROLOGY
(2017)
Article
Endocrinology & Metabolism
Santosh K. Bharti, Flonne Wildes, Chien-Fu Hung, T. C. Wu, Zaver M. Bhujwalla, Marie-France Penet
Article
Pathology
Deyin Xing, Yuehua Liu, Hyeon Jin Park, Inji Baek, Hung Tran, Gloria Cheang, Jorge Novo, Jessica Dillon, Andres Matoso, Emily Farmer, Max A. Cheng, Ya-Chea Tsai, Kara Lombardo, Michael G. Conner, Russell Vang, Chien-Fu Hung, Tzyy-Choou Wu, Wei Song
Article
Obstetrics & Gynecology
Yuehua Liu, Essel Marie B. DeLeon, Salman Okour, Russell Vang, Chien-Fu Hung, Tzyy-Choou Wu, Brigitte M. Ronnett, Deyin Xing
Summary: A 44-year-old woman with menorrhagia and uterine fibroids underwent total laparoscopic hysterectomy, revealing tumors with three distinct morphologies in the uterus. The examination confirmed the presence of FH-deficient atypical leiomyoma and perivascular epithelioid cell tumor, highlighting the importance of thorough examination of uterine mesenchymal tumors with atypical and epithelioid features.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
(2021)
Article
Immunology
Yu-Min Chuang, Noton K. Dutta, James T. Gordy, Victoria L. Campodonico, Michael L. Pinn, Richard B. Markham, Chien-Fu Hung, Petros C. Karakousis
FRONTIERS IN IMMUNOLOGY
(2020)
Article
Multidisciplinary Sciences
Ravi K. Anchoori, Logan George, Ssu-Hsueh Tseng, Brandon Lam, Srinidhi Polkampally, Anjali D. Amiano, Palmer Foran, Hannah Tsingine, Harideep Samanapally, Fernanda Carrizo Velasquez, Samarjit Das, Deyin Xing, Ahmad Bin Salam, Balasubramanyam Karanam, Chien-Fu Hung, Richard B. S. Roden
Summary: Research shows that rendering RPN13 inhibitors chiral and asymmetric can enhance their activity against cancer cells, with the S-isomer being more effective. These compounds induce cytotoxicity through various mechanisms, including binding to RPN13, ATP depletion, mitochondrial dysfunction, apoptosis, and DNA damage repair disruption. Additionally, a synergistic cytotoxic response is observed when combining these inhibitors with cisplatin or doxorubicin in ovarian cancer cell lines, suggesting a potential for combination therapy in the treatment of ovarian cancer.
Article
Multidisciplinary Sciences
Chih-Ping Mao, Shih-Chin Wang, Yu-Pin Su, Ssu-Hsueh Tseng, Liangmei He, Annie A. Wu, Richard B. S. Roden, Jie Xiao, Chien-Fu Hung
Summary: Characterizing individual biomarker protein molecules in patient blood samples using single-molecule imaging techniques holds promise for early disease diagnosis and effective treatment. However, current methods have detection limits that are orders of magnitude higher than needed, making them unsuitable for clinical use. The development of SMAC, with its ability to quantify and characterize protein molecules down to the subfemtomolar range, presents a new avenue for noninvasive disease profiling with single-molecule imaging.
Article
Immunology
Alana MacDonald, Brandon Lam, John Lin, Louise Ferrall, Yu Jui Kung, Ya Chea Tsai, T. -C. Wu, Chien-Fu Hung
Summary: The fusion protein AnnV-IL2 effectively enhances T cell activation and promotes expansion of antigen-specific cells capable of interferon gamma production. Administration of AnnV-IL2 results in a stronger secondary expansion upon antigen rechallenge, indicating durability of AnnV-IL2 mediated responses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Ssu-Hsueh Tseng, Max A. Cheng, Emily Farmer, Louise Ferrall, Yu Jui Kung, Brandon Lam, Ling Lim, T-C Wu, Chien-Fu Hung
Summary: The fusion of albumin to IFN beta (Alb-IFN beta) enhances immune function, prolongs the half-life of IFN beta, and has a significant antitumor effect. Alb-IFN beta can serve as an innovative adjuvant for vaccine development.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, General & Internal
Ying Liu, Maryam Shahi, Karin Miller, Christian F. Meyer, Chien-Fu Hung, T-C Wu, Russell Vang, Deyin Xing
Summary: The diagnosis of pelvic gastrointestinal stromal tumors (GISTs) is difficult due to their atypical presentation and similarity to gynecological neoplasms. This study describes the clinical and pathological features of 20 GIST cases, highlighting the importance of precise diagnosis through immunohistochemical and molecular analysis.
Article
Biochemistry & Molecular Biology
Song-Fong Huang, Sio-Wai Chong, Chun-Wei Huang, Heng-Yuan Hsu, Kuang-Tse Pan, Chien-Fu Hung, Tsung-Han Wu, Chao-Wei Lee, Chia-Hsun Hsieh, Ching-Ting Wang, Pei-Mei Chai, Ming-Chin Yu
Summary: Sorafenib treatment showed varying responses on different target lesions of advanced hepatocellular carcinoma (aHCC). A study found that 19.3% of patients had complete/partial response, 35.4% had stable disease, and 45.2% had progressive disease after six months of sorafenib administration. Poor outcomes were associated with macroscopic venous thrombus and bone metastases, higher AFP levels, and multiple target lesions. ALBI grade A was associated with better outcomes.
Article
Cell Biology
Yu-Jui Kung, Brandon Lam, Ssu-Hsueh Tseng, Alana MacDonald, Hsin-Fang Tu, Suyang Wang, John Lin, Ya Chea Tsai, T. C. Wu, Chien-Fu Hung
Summary: This study aimed to assess the efficacy of combining microbial-based therapy using Salmonella SL7207 with interleukin-2 (IL-2) in the treatment of murine colon carcinoma. The researchers found that Salmonella SL7207 preferentially accumulates in the tumor microenvironment and stimulates localized innate immunity. Administering IL-2 as a fusion protein further enhanced tumor control and overall survival. The study also demonstrated that the combination therapy led to enhanced T cell population and effector function, which were crucial for tumor control. These findings suggest that Salmonella SL7207 and IL-2 may serve as a promising therapeutic approach for inducing T cell-mediated antitumor immunity and long-term tumor control.
JOURNAL OF BIOMEDICAL SCIENCE
(2022)
Article
Oncology
Chien-Wei Peng, Wei Teng, Kar-Wai Lui, Chien-Fu Hung, Wen-Juei Jeng, Chien-Hao Huang, Wei-Ting Chen, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen
Summary: More than one-fifth of HCC patients achieved complete response after the first session of TACE, with better overall survival. Factors such as Child-Turcotte-Pugh class B, tumor burden, tumor extent, AFP levels, and platelet counts may predict the success of complete response after TACE treatment. A tailored follow-up strategy post-TACE should consider different risk factors for early or late recurrence in patients with complete response.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Cell Biology
Ssu-Hsueh Tseng, Li Liu, Shiwen Peng, Jinhwi Kim, Louise Ferrall, Chien-Fu Hung, T. C. Wu
Summary: The study characterized the immune responses of HLA-A2 restricted HPV16 E7-specific CD8 + T cells using a therapeutic naked DNA vaccine in transgenic mice. Spontaneous oral tumors were generated by transfecting oncogenic DNA plasmids into the submucosal oral cavity of the transgenic mice with electroporation. Treatment with the CRT/E7(N53S) DNA vaccine resulted in significant antitumor effects against the spontaneous HPV16 E6/E7-expressing oral tumors in HLA-A2 (AAD) transgenic mice.
JOURNAL OF BIOMEDICAL SCIENCE
(2021)